Ingersoll Rand (IR) 2025 Conference Summary Company Overview - **Company**: Ingersoll Rand (IR) - **Date**: June 10, 2025 - **Speakers**: Vic Kinney (CFO), Matthew Fort (IR and FP&A) Key Industry Insights Demand Trends - **Q1 Organic Orders**: Increased by 3% to 3.5% across both segments (ITS and PST) [2][3] - **Regional Performance**: Positive organic orders momentum observed in all three regions for ITS, with stabilization noted in China [4] - **April Performance**: Demand environment remained stable with no dramatic changes noted [5][6] - **Leading Indicators**: Marketing Qualified Leads (MQLs) continued to trend positively, indicating healthy demand [10] Market Dynamics - **Tariff Impact**: Ongoing uncertainty due to tariffs has created a wait-and-see environment, but demand disruption was less than expected [6][8] - **Short to Medium Cycle Orders**: Contributed significantly to organic orders growth, with long cycle projects also showing positive trends [11][12] Financial Performance Revenue Guidance - **Volume Growth Expectations**: Initial expectations of low single-digit growth revised to a potential decline of about 2% [18] - **Pricing Actions**: All necessary pricing actions have been implemented to offset tariff impacts, with a focus on maintaining dollar neutrality [22][25] Segment Performance - **ITS Segment Growth**: Organic volume up approximately 20-25% since 2020, driven by a combination of product technology and acquisitions [27][29] - **PST Segment Challenges**: Flat performance attributed to the decline in the legacy Ingersoll Rand Medical business post-COVID, which saw a drop from $400 million to around $300 million [37][38] Strategic Initiatives Recurring Revenue Growth - **Target**: Aiming for $1 billion in recurring revenue, with current figures exceeding $300 million [44][46] - **Adoption Year**: 2024 is viewed as a pivotal year for expanding recurring revenue across various product lines [48] M&A Strategy - **Acquisition Focus**: Emphasis on smaller bolt-on acquisitions rather than large transformative deals, with a healthy pipeline of opportunities [66][68] - **Life Sciences Positioning**: The ILC Dover acquisition has strengthened Ingersoll Rand's position in the life sciences sector, with a combined platform valued at $600-700 million [71][72] Margin Expansion Opportunities PST Segment Margins - **Current EBITDA Margins**: Approximately 30%, with a target to reach mid-30s over the medium term [73][78] - **Growth Drivers**: Self-help initiatives, organic growth in the IR Medical business, and integration of ILC Dover assets are expected to contribute to margin improvement [81][82] Conclusion Ingersoll Rand is navigating a complex demand environment with stable order growth and strategic initiatives aimed at enhancing recurring revenue and margin expansion. The company remains focused on leveraging its technological capabilities and M&A strategy to drive future growth.